Deals
Bain Weighs Extending Investment in $12 Billion Drugmaker Stada
- Buyout firm discusses selling Stada stake to newer fund
- Pharma company was seen as one of Europe’s top IPO candidates
Drugs are packaged at the Stada Arzneimittel facility in Bad Vilbel, Germany.
Photographer: Alex Kraus/BloombergThis article is for subscribers only.
Bain Capital is weighing a deal to extend its investment in Stada Arzneimittel AG, one of Europe’s top listing candidates, as it seeks more time to expand the German drugmaker, people with knowledge of the matter said.
The buyout firm is discussing the possibility of selling its 50% stake in Stada to another Bain fund, the people said, asking not to be identified because the information is private. A deal could value the business at more than 10 billion euros ($12.1 billion), according to the people.